NP764764.RAbchDllGPHoWRecG HLCQogkILQnZGzHkPuQXARB-32I
type: Nanopublication
has assertion: NP764764.RAbchDllGPHoWRecG HLCQogkILQnZGzHkPuQXARB-32I130 assertion
has provenance: NP764764.RAbchDllGPHoWRecG HLCQogkILQnZGzHkPuQXARB-32I130 provenance
has publication info: NP764764.RAbchDllGPHoWRecG HLCQogkILQnZGzHkPuQXARB-32I130 publicationInfo
created: 2016-05-13T12:47:31+02:00
rights: http://opendatacommons.org/licenses/odbl/1.0/
rights holder: IBIGroup
subject: SIO_000983
used data: disgenetv3.0rdf
authored by: http://orcid.org/0000-0001-5999-6269
authored by: http://orcid.org/0000-0002-7534-7661
authored by: 0000-0002-9383-528X
authored by: http://orcid.org/0000-0003-0169-8159
authored by: http://orcid.org/0000-0003-1244-7654
created by: http://orcid.org/0000-0003-0169-8159
version: v4.0.0.0

NP764764.RAbchDllGPHoWRecG HLCQogkILQnZGzHkPuQXARB-32I130 assertion
type: Assertion
description: [The beneficial effect of lenalidomide in patients with lower risk myelodysplastic syndrome with del(5q) is associated with significant increases in the proportion of bone marrow erythroid precursor cells and in the frequency of clonogenic progenitor cells, a substantial improvement in the hematopoiesis-supporting potential of bone marrow stroma and significant alterations in the adhesion profile of bone marrow CD34(+) cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine.
evidence: DisGeNET evidence - LITERATURE
SIO_000772: http://identifiers.org/pubmed/19773257
was generated by: ECO_0000203

befree-2016
imported on: 2016-02-19

DisGeNET evidence - LITERATURE
type: ECO_0000212
comment: Gene-disease associations inferred from text-mining the literature.

disgenetv3.0rdf
version: v4.0.0